Answers are grounded in this paper and cite their sources.
Background/Aim Lupus nephritis (LN) is the most severe visceral manifestation of systemic lupus erythematosus and a leading cause of chronic kidney disease. Renal biopsy remains the reference standard for classifying LN, yet it is invasive, costly, and difficult to repeat. This study aimed to develop interpretable predictive models based on routine clinical and laboratory biomarkers to distinguish proliferative from non-proliferative LN and to predict 6-month complete response (CR) after induction therapy. Methods We retrospectively enrolled 174 patients with biopsy-proven LN diagnosed between January 2021 and August 2024 at two Chinese tertiary centers. Baseline demographics, clinical parameters, autoantibody profiles, and renal histopathology according to the 2018 ISN/RPS classification were collected. Patients were grouped as proliferative LN (classes III, IV, and III/IV+V) or non-proliferative LN (classes II, V, and VI). Univariable and multivariable logistic regression were used to identify independent predictors; model discrimination was quantified with receiver operating characteristic curves and the area under the curve (AUC), and internal validation was performed by bootstrap resampling (1000 resamples) with optimism-corrected performance estimates. Results Overall, 117 patients (67.2%) had proliferative LN and 57 (32.8%) had non-proliferative LN. Proliferative LN was characterized by more hypertension, more severe anemia, lower estimated glomerular filtration rate (eGFR), higher urinary red blood cell count, and higher positivity rates of anti-dsDNA, anti-C1q, anti-nucleosome, anti-histone, and p-ANCA antibodies. Multivariable analysis identified lower eGFR (OR 0.978, 95% CI 0.966–0.989, P<0.001), higher urinary red blood cell count (OR 1.012, 95% CI 1.003–1.021, P = 0.007), higher anti-dsDNA antibody (OR 1.002, 95% CI 1.001–1.003, P = 0.012), and higher anti-C1q antibody (OR 1.047, 95% CI 1.015–1.080, P = 0.003) as independent predictors of proliferative LN. The combined anti-dsDNA/anti-C1q model yielded an AUC of 0.7877. In proliferative LN, higher age, higher baseline eGFR, higher anti-dsDNA antibody, and higher anti-C1q antibody independently predicted 6-month CR, although the anti-dsDNA association was attenuated to borderline significance after adjustment for the histological chronicity index (P = 0.053), whereas the anti-C1q association remained significant (P = 0.012); in non-proliferative LN, only baseline urine protein-to-creatinine ratio was independently predictive. Conclusion Baseline eGFR, urinary red blood cell count, anti-dsDNA antibody, and anti-C1q antibody provide a non-invasive means to estimate the likelihood of proliferative LN and may help prioritize patients for timely renal biopsy; however, given the moderate discrimination of the present models, these markers are intended to complement rather than replace renal biopsy. Anti-C1q antibody additionally predicts short-term induction response (an early, intermediate endpoint) in proliferative LN, whereas anti-dsDNA antibody shows only a possible association with response that requires confirmation in future studies; these markers support their integration into interpretable, data-driven risk-stratification algorithms for personalized management, pending external validation in prospective, multi-center cohorts.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: